Keyphrases
Population-based Study
100%
Atopic Dermatitis
100%
BNT162b2
100%
MRNA Vaccine
100%
Adjusted Hazard Ratio
50%
COVID-19
40%
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
40%
Immunosuppressive Drugs
30%
Israel
20%
Hospitalization
20%
Adult Patients
20%
Adjusted Odds Ratio
20%
Odds Ratio
10%
Vaccination
10%
Decreased Risk
10%
Population-based Cohort Study
10%
Logistic Regression Analysis
10%
Retrospective Analysis
10%
Highly Effective
10%
Messenger RNA (mRNA)
10%
Vaccination Rate
10%
Vaccinated Patients
10%
Adulthood-onset
10%
Vaccine Dose
10%
Immunosuppressive Medication
10%
Moderate-to-severe Atopic Dermatitis
10%
BNT162b2 Vaccine
10%
Messenger RNA Vaccine
10%
Multivariate Cox Regression Analysis
10%
Coronavirus Disease 2019 Vaccination
10%
Coronavirus Disease 2019 Vaccine
10%
Vaccine Development
10%
Vaccine-induced Immunity
10%
Heath Services
10%
Specific Analysis
10%
Medicine and Dentistry
Atopic Dermatitis
100%
Messenger RNA
100%
COVID-19
54%
Hazard Ratio
45%
Immunosuppressive Drug
36%
Infection
36%
Severe Acute Respiratory Syndrome Coronavirus 2
36%
Odds Ratio
27%
Drug Therapy
9%
Prevalence
9%
Cohort Analysis
9%
Proportional Hazards Model
9%
Logistic Regression Analysis
9%
RNA Vaccine
9%
Pharmacology, Toxicology and Pharmaceutical Science
Atopic Dermatitis
100%
Messenger RNA
100%
Disease
54%
Coronavirinae
45%
Immunosuppressive Agent
36%
SARS Coronavirus
36%
Infection
27%
Cohort Study
9%
Prevalence
9%
Coronavirus Infection
9%
RNA Vaccine
9%